Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2011

01.08.2011 | Breast Oncology

Success and Failure of Primary Medical, Nonoperative Management In Breast Cancer

verfasst von: Seraina Margaretha Schmid, MD, Aleksandra Anna Modlasiak, MD, Mary Elizabeth Myrick, MD, Nerbil Kilic, MD, Carsten Thomas Viehl, MD, Andreas Schötzau, MS, Uwe Güth, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Nonoperative but systemic therapy as first-line management is offered to some patients with breast cancer (BC) who have assumed limited life expectancy, such as older women or those who have distant metastases at initial presentation. We evaluated rates of and predicting factors for success and failure of this therapy approach.

Methods

Seventy-five patients who were initially treated only systemically, and cases in which local control while avoiding surgery was the intended long-term therapy goal were analyzed. Additionally, two stage-dependent subgroups were distinguished (A: stage I-III, n = 31; B: stage IV, n = 44). Failure of therapy was defined as when secondary surgery had to be performed due to locoregional progression or in case of no surgery when severe locoregional clinical signs/symptoms were observed during the further course.

Results

Patients in group A were older than those in group B (81 vs. 67.5 years; P < 0.001) and showed an increased survival (5-year rates: 40.2% vs. 24.3%). In 24 patients of the entire cohort (32%), secondary surgery had to be performed; surgery was performed more often in group A (58.1% vs. 13.6%). In the cases in which no surgery was performed (n = 51), 11 women (21.6%) suffered from severe locoregional symptoms in the palliative situation (A: n = 1; B: n = 10). Although the presence of stage IV was a significant factor for therapy success (odds ratio (OR), 2.59; 95% confidence interval (CI), 0.95–7.05; P = 0.039), skin involvement was associated with failure of therapy (OR, 3.57; 95% CI, 1.16–11.11; P = 0.031).

Conclusions

Nonoperative treatment may be offered to selected patients with BC who have assumed limited life expectancy. These women must be openly informed that this approach is not successful in nearly half of the cases.
Literatur
1.
Zurück zum Zitat Fennessy M, Bates T, MacRae K, et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg. 2004;91:699–704.PubMedCrossRef Fennessy M, Bates T, MacRae K, et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg. 2004;91:699–704.PubMedCrossRef
2.
Zurück zum Zitat Fentiman IS, Christiaens MR, Paridaens R, et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer. 2003;39:309–16.PubMedCrossRef Fentiman IS, Christiaens MR, Paridaens R, et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer. 2003;39:309–16.PubMedCrossRef
3.
Zurück zum Zitat Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2006;CD004272. Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2006;CD004272.
4.
Zurück zum Zitat Kenny F, Robertson J, Ellis I et al. Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast. 1998;7:335–9.CrossRef Kenny F, Robertson J, Ellis I et al. Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast. 1998;7:335–9.CrossRef
5.
Zurück zum Zitat Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol. 2003;14:414–20.PubMedCrossRef Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol. 2003;14:414–20.PubMedCrossRef
6.
Zurück zum Zitat Atkin GK, Scott MA, Wiggins JE, Callam MJ. The incidence, indications and outcome for the non-operative management of breast cancer. J Surg Oncol. 2007;96:137–43.PubMedCrossRef Atkin GK, Scott MA, Wiggins JE, Callam MJ. The incidence, indications and outcome for the non-operative management of breast cancer. J Surg Oncol. 2007;96:137–43.PubMedCrossRef
7.
Zurück zum Zitat Verkooijen HM, Fioretta GM, Rapiti E, et al. Patients’ refusal of surgery strongly impairs breast cancer survival. Ann Surg. 2005;242:276–80.PubMedCrossRef Verkooijen HM, Fioretta GM, Rapiti E, et al. Patients’ refusal of surgery strongly impairs breast cancer survival. Ann Surg. 2005;242:276–80.PubMedCrossRef
8.
Zurück zum Zitat Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol. 2006;13:776–82.PubMedCrossRef Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol. 2006;13:776–82.PubMedCrossRef
9.
Zurück zum Zitat Bafford AC, Burstein HJ, Barkley CR, et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009;115:7–12.PubMedCrossRef Bafford AC, Burstein HJ, Barkley CR, et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009;115:7–12.PubMedCrossRef
10.
Zurück zum Zitat Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008;247:732–8.PubMedCrossRef Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008;247:732–8.PubMedCrossRef
11.
Zurück zum Zitat Fields RC, Jeffe DB, Trinkaus K, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol. 2007;14:3345–51.PubMedCrossRef Fields RC, Jeffe DB, Trinkaus K, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol. 2007;14:3345–51.PubMedCrossRef
12.
Zurück zum Zitat Gnerlich J, Jeffe DB, Deshpande AD, et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol. 2007;14:2187–94.PubMedCrossRef Gnerlich J, Jeffe DB, Deshpande AD, et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol. 2007;14:2187–94.PubMedCrossRef
13.
Zurück zum Zitat Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002;132:620–6; discussion 626–7. Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002;132:620–6; discussion 626–7.
14.
Zurück zum Zitat Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24:2743–9.PubMedCrossRef Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24:2743–9.PubMedCrossRef
15.
Zurück zum Zitat Edge S, Byrd D, Compton C, et al. AJCC cancer staging manual. New York: Springer; 2009. Edge S, Byrd D, Compton C, et al. AJCC cancer staging manual. New York: Springer; 2009.
16.
Zurück zum Zitat Sobin L, Gospodarowicz M, Wittekind C (2009) UICC TNM classification of malignant tumors Oxford. Wiley-Blackwell. Sobin L, Gospodarowicz M, Wittekind C (2009) UICC TNM classification of malignant tumors Oxford. Wiley-Blackwell.
17.
Zurück zum Zitat Guth U, Jane Huang D, Holzgreve W, et al. T4 breast cancer under closer inspection: a case for revision of the TNM classification. Breast. 2007;16:625–36.PubMedCrossRef Guth U, Jane Huang D, Holzgreve W, et al. T4 breast cancer under closer inspection: a case for revision of the TNM classification. Breast. 2007;16:625–36.PubMedCrossRef
18.
Zurück zum Zitat Holmes C, Muss H. Breast cancer in older women. In: Singletary S, Robb G, Hortobagyi G (editors). Advanced therapy of breast cancer, 2nd ed. Hamilton: Decker 2004:727–42. Holmes C, Muss H. Breast cancer in older women. In: Singletary S, Robb G, Hortobagyi G (editors). Advanced therapy of breast cancer, 2nd ed. Hamilton: Decker 2004:727–42.
19.
Zurück zum Zitat Rao VS, Garimella V, Hwang M, Drew PJ. Management of early breast cancer in the elderly. Int J Cancer. 2007;120:1155–60.PubMedCrossRef Rao VS, Garimella V, Hwang M, Drew PJ. Management of early breast cancer in the elderly. Int J Cancer. 2007;120:1155–60.PubMedCrossRef
20.
Zurück zum Zitat Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA. 2000;284:2476–82.PubMedCrossRef Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA. 2000;284:2476–82.PubMedCrossRef
21.
Zurück zum Zitat Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst. 1994;86:1766–70.PubMedCrossRef Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst. 1994;86:1766–70.PubMedCrossRef
22.
Zurück zum Zitat Guth U, Huang DJ, Dirnhofer S, et al. Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision. Cancer J. 2009;15:81–6.PubMedCrossRef Guth U, Huang DJ, Dirnhofer S, et al. Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision. Cancer J. 2009;15:81–6.PubMedCrossRef
Metadaten
Titel
Success and Failure of Primary Medical, Nonoperative Management In Breast Cancer
verfasst von
Seraina Margaretha Schmid, MD
Aleksandra Anna Modlasiak, MD
Mary Elizabeth Myrick, MD
Nerbil Kilic, MD
Carsten Thomas Viehl, MD
Andreas Schötzau, MS
Uwe Güth, MD
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2011
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1592-8

Weitere Artikel der Ausgabe 8/2011

Annals of Surgical Oncology 8/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.